Osilodrostat: First Approval.
Drugs
; 80(5): 495-500, 2020 Apr.
Article
em En
| MEDLINE
| ID: mdl-32141023
ABSTRACT
Osilodrostat (Isturisa®) is an orally available small molecule 11ß-hydroxylase inhibitor that is being developed by Novartis for the treatment of Cushing's disease. Based on results from a pivotal phase III trial, osilodrostat was approved in the EU for use in the treatment of endogenous Cushing's syndrome in adults and is under regulatory review in the USA for the treatment of Cushing's disease. This article summarises the milestones in the development of osilodrostat leading to this first approval.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Piridinas
/
Esteroide 11-beta-Hidroxilase
/
Aprovação de Drogas
/
Síndrome de Cushing
/
Inibidores Enzimáticos
/
Imidazóis
Idioma:
En
Ano de publicação:
2020
Tipo de documento:
Article